Comparative Pharmacology
Head-to-head clinical analysis: DIETHYLSTILBESTROL versus GYNODIOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIETHYLSTILBESTROL versus GYNODIOL.
DIETHYLSTILBESTROL vs GYNODIOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic nonsteroidal estrogen that binds to estrogen receptors (ERα/ERβ), activating estrogen-responsive gene transcription, leading to proliferation of estrogen-sensitive tissues.
Estradiol acts by binding to nuclear estrogen receptors, which modulate gene transcription and lead to the development and maintenance of female reproductive tissues and secondary sexual characteristics. Norethindrone acetate is a progestin that suppresses gonadotropin secretion and induces secretory changes in the endometrium.
0.5-2 mg orally once daily for palliative treatment of advanced prostate cancer; 5-15 mg orally once daily for prevention of postpartum breast engorgement.
1 tablet (ethinylestradiol 0.035 mg/norethisterone 1 mg) orally once daily for 21 days, followed by 7 days of placebo or hormone-free interval.
None Documented
None Documented
Clinical Note
moderateDiethylstilbestrol + Digoxin
"Diethylstilbestrol may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateDiethylstilbestrol + Digitoxin
"Diethylstilbestrol may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateDiethylstilbestrol + Deslanoside
"Diethylstilbestrol may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateDiethylstilbestrol + Acetyldigitoxin
Terminal elimination half-life is approximately 24 hours (range 20-30 hours) in adults; prolonged in hepatic impairment.
Terminal half-life approximately 24-30 hours; steady-state reached by 5-7 days.
Primarily renal (90% as glucuronide and sulfate conjugates), with less than 5% excreted unchanged in urine; biliary/fecal elimination accounts for about 10%.
Renal 50-80% as metabolites and conjugates; biliary/fecal 10-20%; unchanged drug <5%.
Category C
Category C
Estrogen
Estrogen
"Diethylstilbestrol may decrease the cardiotoxic activities of Acetyldigitoxin."